Phaseline

Targets › SCTR

SCTR (Secretin receptor): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 3, 1 Phase 4; Oncology, Gastroenterology; next expected readout Mar 2027.

G protein-coupled receptor activated by secretin (SCT), which is involved in different processes such as regulation of the pH of the duodenal content, food intake and water homeostasis. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and activates cAMP-dependent pathway. (UniProt, P47872)

Open in Phaseline: the race on SCTR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Mayo ClinicSecretin (human synthetic) - ChiRhoClin
Secretin receptor agonist
SCTRPhase 4Exocrine Pancreatic InsufficiencyMar 2027
Johns Hopkins UniversitySecretin Synthetic Human
Secretin receptor agonist
SCTRPhase 3Pancreas CancerDec 2028

Conditions

Pancreas Cancer (1) Exocrine Pancreatic Insufficiency (1)

Modalities

small molecule (2)

Companies

Johns Hopkins University (1) Mayo Clinic (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.